Health-economic aspects of cystic fibrosis screening and therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293404" target="_blank" >RIV/00064203:_____/14:10293404 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10293404

Výsledek na webu

<a href="http://dx.doi.org/10.1183/1025448x.10010613" target="_blank" >http://dx.doi.org/10.1183/1025448x.10010613</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1183/1025448x.10010613" target="_blank" >10.1183/1025448x.10010613</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Health-economic aspects of cystic fibrosis screening and therapy

Popis výsledku v původním jazyce

There is an increasing need to manage cost-effectiveness issues of novel or relatively expensive technologies that are currently in use or being proposed for the treatment of cystic fibrosis (CF) (e.g. cystic fibrosis transmembrane conductance regulator(CFTR) modulation therapy). Health-economic evaluations of rising pharmacotherapeutic costs, as the major driver of overall cost, have to be part of the cost analysis of chronic and progressive (rare) diseases like CF that may require lifelong therapy. Total costs include not only direct healthcare costs but also the cost of lost productivity by both patients and family caregivers. When considering the results of cost-effectiveness analysis of new technologies associated with the management of CF, it isunreasonable to expect that the incremental cost-effectiveness ratio to be less than the generally applied thresholds (willingness to pay) for other common diseases. Therefore, when assessing CF and other rare diseases, such analyses sho

Název v anglickém jazyce

Health-economic aspects of cystic fibrosis screening and therapy

Popis výsledku anglicky

There is an increasing need to manage cost-effectiveness issues of novel or relatively expensive technologies that are currently in use or being proposed for the treatment of cystic fibrosis (CF) (e.g. cystic fibrosis transmembrane conductance regulator(CFTR) modulation therapy). Health-economic evaluations of rising pharmacotherapeutic costs, as the major driver of overall cost, have to be part of the cost analysis of chronic and progressive (rare) diseases like CF that may require lifelong therapy. Total costs include not only direct healthcare costs but also the cost of lost productivity by both patients and family caregivers. When considering the results of cost-effectiveness analysis of new technologies associated with the management of CF, it isunreasonable to expect that the incremental cost-effectiveness ratio to be less than the generally applied thresholds (willingness to pay) for other common diseases. Therefore, when assessing CF and other rare diseases, such analyses sho

Druh

C - Kapitola v odborné knize

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Cystic Fibrosis

ISBN

978-1-84984-051-4

Počet stran výsledku

16

Strana od-do

315-330

Počet stran knihy

319

Název nakladatele

European Respiratory Society

Místo vydání

Sheffield

Kód UT WoS kapitoly

—